Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Dianthus Therapeutics, Inc. DNTH

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.0M
▼ 67.3% YoY
$-162.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 2.0M
Revenue, FY2025 · full 10-year series below
Revenue $M Net income $M
FY2025 · Revenue 2.0 · Net income -162.3
-100M-200M
2016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -8739.3%
-5000%
201620202025
ROE
FY2025 · ROE -38.4%
-20%-40%
201620202025
Three returns, three denominators.

Each USD of equity lost 38 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2022 · FCF -29.4
-25.0M-50.0M
201620202025

Total assetsUSD 530.9M
EquityUSD 493.4M
CashUSD 51.1M
Current ratio13.32×

Equity funds 93% of total assets.

The 10-year record

10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
DNTH, 10-year financial record
Metric 2025202420232022202120202019201820172016
Revenue $B0.00.00.0◌◌◌0.00.00.00.0
Operating income $B−0.2−0.1−0.0−0.0−0.1−0.1−0.1−0.1−0.0−0.0
EBITDA $B−0.2−0.1−0.0−0.0−0.1−0.1−0.1−0.1−0.0−0.0
Income tax $B0.00.00.00.00.00.00.00.00.00.0
Net income $B−0.2−0.1−0.0−0.0−0.1−0.1−0.1−0.1−0.0−0.0
Free cash flow $B◌◌◌−0.0−0.1−0.1−0.1−0.0−0.0−0.0
EPS, diluted $−4.20−2.55−8.45−32.57−1.29−1.71−2.07−3.13−19.12−65.15
Dividend / sh $0.000.000.00◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————
ROE %−38.4−32.6———−52.6−53.5———
Shares out B0.040.030.010.000.060.050.040.030.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 38 reconciliationsAUDITED

Reconciled in 10 of the 10 fiscal years we could check. 20 checks were skipped: the balance sheet is not tagged before 2017. Nine checks were skipped: EPS is not tagged before 2016.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2016

Share this section

Download image